Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT02778594Phase 1Completed
Phase 1, randomised, double-blind trial of nebicapone in Parkinson's disease (PD) (4 arms), sponsored by BIAL. Primary endpoints: Maximum observed plasma drug concentration at 24 hours, Time of occurrence of Cmax at 24 hours and 3 more. Started Sep 2005; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT02778594.